Upcoming & Enrolling Adult Cystic Fibrosis Clinical Trials
The studies listed below will soon be or are currently enrolling participants. Our list of upcoming studies is constantly evolving. Please contact our research team to learn about studies in our pipeline that may not be listed here!
To learn more about upcoming clinical trials in CF, visit the Cystic Fibrosis Foundation’s Clinical Trials Finder.
Last updated May 9th, 2024.
This is an accordion element with a series of buttons that open and close related content panels.
MAYFLOWERS-OB-20 | Pregnancy in CF
“This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.” – CFF Trial Finder Profile
Principal Investigator: Erin Lowery, MD
Lead Research Coordinator: Melanie Nelson
Key Inclusion Criteria:
– 16 Years and Older
– Currently Pregnant
– No FEV1 requirement
Time Commitment: Up to 9 study visits over 35 months (approximately 3 years). Your study visits may last about 2 to 3 hours. Study visits will be done at the same time as your scheduled clinical care visits.
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
STOP360-IP-22 | Antibiotic Treatment of Pulmonary Exacerbations
“This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD
Lead Research Coordinator: Nikki Cole
Key Inclusion Criteria:
– 6 Years and Older
– Positive Pseudomonas aeruginosa culture in last two years
Time Commitment: 3 study visits over 48 days.
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
VX21-522-001 | Inhaled mRNA Therapy
“This study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA), in adults with CF whose mutations are not responsive to CFTR modulator therapy.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD
Lead Research Coordinator: Nikki Cole
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
Ongoing Adult Cystic Fibrosis Clinical Trials
The clinical trials listed below are currently ongoing and are no longer accepting new participants. Our studies are both investigational and observational. We enjoy working with families from all around the Midwest. Please contact our research team to learn about clinical trials in our pipeline that may not be listed here!
Last updated May 9th, 2024.
This is an accordion element with a series of buttons that open and close related content panels.
VX20-121-104 | Open Label Once a Day Modulator
“The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.” – ClinicalTrials.gov Profile
Principal Investigator: Andrew Braun, MD
Lead Research Coordinators: Cate Wilkinson and Nikki Cole
See ClinicalTrials.gov profile here.
PROMISE-OB-18 | Observational Trikafta Study
“PROMISE is a postapproval, real-world, observational study to understand the effects of elexacaftor/tezacaftor/ivacaftor (ETI) in clinical use in the United States.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD
Lead Research Coordinator: Megan Devereaux
See the CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.